Clene Inc. Stock News

Zacks Investment Research downgraded shares of Clene (NASDAQ:CLNN) from a buy rating to a hold rating in a report published on Tuesday, Zacks.com reports. According to Zacks, Clene Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of unique therapeutics for neurodegenerative diseases. Clene Nanomedicine Inc., formerly known as Tottenham Acquisition I []

Clene (NASDAQ:CLNN) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report released on Tuesday, Zacks.com reports. According to Zacks, Clene Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of unique therapeutics for neurodegenerative diseases. Clene Nanomedicine Inc., formerly known as Tottenham Acquisition I []

Shares of Clene Inc. (NASDAQ:CLNN) have been assigned a consensus rating of Buy from the six brokerages that are presently covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued ratings on the stock in the last []

The average of price targets set by Wall Street analysts indicates a potential upside of 238.3% in Clene Inc. (CLNN). While the effectiveness of this highly sought-after metric is questionable, the po

The average of price targets set by Wall Street analysts indicates a potential upside of 238.3% in Clene Inc. (CLNN). While the effectiveness of this highly sought-after metric is questionable, the po

SALT LAKE CITY, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biophar

SALT LAKE CITY, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries Clene and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease with potential first-in-class nanotherapeutics, today announced the completion of enrollment in the HEALEY ALS Platform Trial, led by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital. Clenes lead drug candidate, CNM-Au8® , a gold nanocrystal suspension, which has received U.S. Food and Drug Administration (FDA) Orphan Drug designation for the treatment of amyotrophic lateral sclerosis (ALS), is one of several drugs being evaluated in this innovative platform trial.

SALT LAKE CITY, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biophar

CNM-Au8® , a catalytically active gold nanocrystal suspension, significantly improved brain energetic metabolism in Parkinson's patients CNM-Au8® , a catalytically active gold nanocrystal suspension

SALT LAKE CITY, Sept. 09, 2021 (GLOBE NEWSWIRE) --  Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopha

Phase 2 REPAIR program demonstrated statistically significant improvements in brain energetic metabolism with CNM-Au8®, a gold nanocrystal suspension

Achieved a statistically significant increase in the Phase 2 program's primary endpoint  (mean change in brain NAD+/NADH ratio)

Clene is a developer of proprietary, patented, nanocatalysis therapy for neurodegenerative diseases. They have ongoing phase 2 trials in multiple sclerosis, Parkinson's disease and amyotrophic lateral

SALT LAKE CITY, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharma

If you're thinking about going for the ultimate contrarian trade, here is a list of the most heavily shorted stocks. The post 7 Highly Shorted Stocks Heading Into Q3 2021 appeared first on InvestorPla